NASDAQ:GBT Global Blood Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Global Blood Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $31.95 -0.33 (-1.02%) (As of 06/30/2022 04:00 PM ET) Add Compare Share Today's Range$31.41▼$32.9250-Day Range$22.30▼$34.8452-Week Range$21.65▼$40.69Volume1.58 million shsAverage Volume1.35 million shsMarket Capitalization$2.08 billionP/E RatioN/ADividend YieldN/APrice Target$58.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GBT Stock Forecast (MarketRank)Overall MarketRank™1.95 out of 5 starsMedical Sector651st out of 1,433 stocksPharmaceutical Preparations Industry303rd out of 684 stocksAnalyst Opinion: 3.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 - 3.4 Analyst's Opinion Consensus RatingGlobal Blood Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $58.67, Global Blood Therapeutics has a forecasted upside of 83.6% from its current price of $31.95.Amount of Analyst CoverageGlobal Blood Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 4.9 Community Rank Outperform VotesGlobal Blood Therapeutics has received 560 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGlobal Blood Therapeutics has received 192 “underperform” votes. (Add your “underperform” vote.)Community SentimentGlobal Blood Therapeutics has received 74.47% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote “Outperform” if you believe GBT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGlobal Blood Therapeutics does not currently pay a dividend.Dividend GrowthGlobal Blood Therapeutics does not have a long track record of dividend growth. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Global Blood Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,335.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Global Blood Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Global Blood Therapeutics are expected to grow in the coming year, from ($4.64) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Global Blood Therapeutics is -6.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Global Blood Therapeutics is -6.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlobal Blood Therapeutics has a P/B Ratio of 10.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Global Blood Therapeutics (NASDAQ:GBT)Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.Read More GBT Stock News HeadlinesJune 30, 2022 | finance.yahoo.comGlobal Blood (GBT) Initiates Phase II Study on SCD CandidateJune 29, 2022 | finance.yahoo.comWhy Global Blood Therapeutics Trended Upward TodayJune 29, 2022 | seekingalpha.comGBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell diseaseJune 29, 2022 | finance.yahoo.comGBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell DiseaseJune 29, 2022 | americanbankingnews.comGlobal Blood Therapeutics (NASDAQ:GBT) Price Target Lowered to $36.00 at JPMorgan Chase & Co.June 24, 2022 | americanbankingnews.comPhilip A. Pizzo Sells 1,260 Shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) StockJune 21, 2022 | seekingalpha.comGlobal Blood Therapeutics: Powerhouse Of The FutureJune 21, 2022 | seekingalpha.comGlobal Blood Therapeutics (GBT) Presents at the William Blair 42nd Annual Growth Stock Conference - SlideshowJune 16, 2022 | finance.yahoo.comNFL Running Back Tevin Coleman and Family Team Up with GBT to Share Playbook for Families Affected by Sickle Cell DiseaseJune 13, 2022 | finance.yahoo.comNew GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell DiseaseJune 12, 2022 | americanbankingnews.comBrokerages Set Global Blood Therapeutics, Inc. (NASDAQ:GBT) Price Target at $55.42June 12, 2022 | americanbankingnews.comGlobal Blood Therapeutics (NASDAQ:GBT) Reaches New 12-Month Low at $22.35June 10, 2022 | finance.yahoo.comHow Global Blood Therapeutics Thinks It Can Take On Crispr's Gene EditingSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GBT CUSIPN/A CIK1629137 Webwww.gbt.com Phone(650) 741-7700FaxN/AEmployees457Year FoundedN/ACompany Calendar Last Earnings5/04/2022Today6/30/2022Next Earnings (Estimated)8/02/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$58.67 High Stock Price Forecast$75.00 Low Stock Price Forecast$31.00 Forecasted Upside/Downside+83.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($4.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-303.09 million Net Margins-146.82% Pretax Margin-146.57% Return on Equity-129.74% Return on Assets-40.85% Debt Debt-to-Equity Ratio4.34 Current Ratio8.52 Quick Ratio7.74 Sales & Book Value Annual Sales$194.75 million Price / Sales10.68 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book10.48Miscellaneous Outstanding Shares65,098,000Free Float62,038,000Market Cap$2.08 billion OptionableOptionable Beta1.11 Global Blood Therapeutics Frequently Asked Questions Should I buy or sell Global Blood Therapeutics stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Global Blood Therapeutics stock. View analyst ratings for Global Blood Therapeutics or view top-rated stocks. What is Global Blood Therapeutics' stock price forecast for 2022? 12 equities research analysts have issued 1 year price objectives for Global Blood Therapeutics' stock. Their GBT stock forecasts range from $31.00 to $75.00. On average, they predict Global Blood Therapeutics' share price to reach $58.67 in the next twelve months. This suggests a possible upside of 83.6% from the stock's current price. View analysts' price targets for Global Blood Therapeutics or view top-rated stocks among Wall Street analysts. How has Global Blood Therapeutics' stock price performed in 2022? Global Blood Therapeutics' stock was trading at $29.27 on January 1st, 2022. Since then, GBT shares have increased by 9.2% and is now trading at $31.95. View the best growth stocks for 2022 here. When is Global Blood Therapeutics' next earnings date? Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Global Blood Therapeutics. How were Global Blood Therapeutics' earnings last quarter? Global Blood Therapeutics, Inc. (NASDAQ:GBT) released its quarterly earnings data on Wednesday, May, 4th. The company reported ($1.26) earnings per share for the quarter, beating analysts' consensus estimates of ($1.29) by $0.03. The company earned $55.20 million during the quarter, compared to the consensus estimate of $56.13 million. Global Blood Therapeutics had a negative net margin of 146.82% and a negative trailing twelve-month return on equity of 129.74%. The company's revenue was up 41.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.21) EPS. View Global Blood Therapeutics' earnings history. Who are Global Blood Therapeutics' key executives? Global Blood Therapeutics' management team includes the following people: Dr. Ted W. Love M.D., Pres, CEO & Director (Age 63, Pay $1.06M)Mr. Jeffrey S. Farrow, CFO & Principal Accounting Officer (Age 60, Pay $672.67k)Ms. Jung E. Choi, Chief Bus. & Strategy Officer (Age 52, Pay $645k)Mr. David L. Johnson, Chief Commercial Officer (Age 53, Pay $661.5k)Dr. Kim Smith-Whitley M.D., Exec. VP and Head of R&D (Age 61, Pay $654k)Dr. David R. Phillips, Founder & AdvisorDr. Matthew P. Jacobson Ph.D., Founder & AdvisorDr. Andrej Sali Ph.D., Founder & AdvisorMs. Nazila Habibizad, Exec. VP of Operations (Age 59)Stephanie Yao, Sr. Director of Corp. Communications & Investor Relations What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO? 13 employees have rated Global Blood Therapeutics CEO Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among Global Blood Therapeutics' employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Global Blood Therapeutics' key competitors? Some companies that are related to Global Blood Therapeutics include Teva Pharmaceutical Industries (TEVA), Grifols (GRFS), Maravai LifeSciences (MRVI), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Intra-Cellular Therapies (ITCI), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Hypera (HYPMY), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Cerevel Therapeutics (CERE) and Karuna Therapeutics (KRTX). View all of GBT's competitors. What other stocks do shareholders of Global Blood Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Square (SQ). When did Global Blood Therapeutics IPO? (GBT) raised $102 million in an initial public offering (IPO) on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers. What is Global Blood Therapeutics' stock symbol? Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT." How do I buy shares of Global Blood Therapeutics? Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Global Blood Therapeutics' stock price today? One share of GBT stock can currently be purchased for approximately $31.95. How much money does Global Blood Therapeutics make? Global Blood Therapeutics (NASDAQ:GBT) has a market capitalization of $2.08 billion and generates $194.75 million in revenue each year. The company earns $-303.09 million in net income (profit) each year or ($4.87) on an earnings per share basis. How many employees does Global Blood Therapeutics have? Global Blood Therapeutics employs 457 workers across the globe. How can I contact Global Blood Therapeutics? Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for Global Blood Therapeutics is www.gbt.com. The company can be reached via phone at (650) 741-7700 or via email at [email protected]. This page (NASDAQ:GBT) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
